Physician profile
Mark B Skinner
NPI 1699860809
$3,081.72
in general payments reported to CMS, 2019-2025
15 companies · $973 in 2025
The $973 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $524 · 2023: $698 · 2024: $587 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $725.01 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $543.54 | 2021-2025 | |
| Axsome Therapeutics, INC. | $470.72 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $461.94 | 2021-2025 | Caplyta |
| Lundbeck LLC | $192.75 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $189.39 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $111.99 | 2021-2024 | Trintellix |
| Alkermes, INC. | $99.95 | 2022-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $80.78 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $70.50 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Indivior INC. | $60.44 | 2022-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $29.27 | 2021 | |
| Janssen Biotech, INC. | $15.84 | 2023 | |
| Noven Pharmaceuticals, INC. | $15.46 | 2021 | |
| Tris Pharma INC | $14.14 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.